openPR Logo
Press release

Lifitegrast Ophthalmic Solution Market: Growing Awareness Regarding Dry Eye Syndrome among People is Expected to Drive the Market Growth

01-13-2017 01:51 PM CET | Health & Medicine

Press release from: TMR

Lifitegrast Ophthalmic Solution Market: Growing Awareness

Dry eye syndrome (DES) also called as dry eye disease (DED) or keratoconjunctivitis sicca (KCS), is a chronic disease that leads to lack of tears to maintain sufficient moisture to the eye. This condition is either a sign of less production of tears or quick drying of the film of tears. More than 300 million people are estimated to suffer from this condition. This medical condition is associated with symptoms such as pain, itching, redness, blurred vision, light sensitivity, burning and inflammation.

Request a PDF Brochure with Report Analysis: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13844

The key contributing reasons for dry eye syndrome include dry environment, sun exposure, allergy, smoke exposure, heat or chemical burns, previous surgery, aging, contact lenses or infection. Presently, variety of treatment approaches are available to manage dry eye syndrome such as lubricant treatments, autologous serum eye drops, anti-inflammatory treatments, and surgery.

Lifitegrast is an integrin antagonist that reduces T-cell-mediated inflammation associated with dry eye disease (DED). This molecule was in pipeline for past few years and several clinical trials have been performed to test its efficacy in treating the signs and symptoms of dry eye syndrome. In July 2016, lifitegrast ophthalmic solution (5%) under the brand name Xiidra by Shire plc was granted an approval from the U.S. Food and Drug Administration (FDA) for treating dry eye syndrome. Xiidra is a twice-daily eye drop solution and only prescription drops indicated for the management of both signs and symptoms of this condition. Shire is expected to launch Xiidra in the United States in the third quarter of 2016.

Being the first U.S. FDA approved product to treat both signs and symptoms of DES, the market for Xiidra is expected to grow exponentially in the near future. The key driving factor attributable to the growing potential of the market is the rising prevalence of dry eye syndrome worldwide. Increasing demand for advance treatment approaches is set to drive the market growth for lifitegrast ophthalmic solution.

High incidences of other conditions that can affect the normal eye functions, such as diabetes, is another underpinning factor boosting the prevalence of dry eye syndrome. Apart from diabetes, other conditions that can lead to dry eye syndrome include vitamin A deficiency, rheumatoid arthritis, lupus, and thyroid disorders. The growing geriatric population around the world has also led to an increase in the overall prevalence of dry eye syndrome.

Earlier, the dry eye syndrome was ignored by patients as the problems created by the condition were not debilitating. However, growing amount of awareness about dry eye syndrome among the people is expected to drive the market growth exponentially. Additionally, awareness regarding the management of this condition is assisting the market growth. The growing problem of pollution is often an underlying factor for dry eye disease and hence the rising industrialization will augment the prevalence of the condition. However, the increasing awareness about the diagnosis and management of the disease has led to more patient awareness towards the disease.

Browse Research Report: http://www.transparencymarketresearch.com/lifitegrast-ophthalmic-solution-market.html

The market for Xiidra is expected to grow exponentially in the near future owing to the growth in dry eye syndrome market. Despite the rising prevalence of dry eye syndrome, the underdiagnosis of dry eye syndrome is restraining the expected growth trajectory. Additionally, the trend of self-medication among the patients remains a major restraint to the market growth of lifitegrast ophthalmic solution during the forecast period from 2016 to 2024.

Some of the major companies in the global dry eye syndrome market are Novartis AG, NicOx SA, Allergan Inc., Bridge Pharma Inc., Cellzome GmbH, and Santen Pharmaceutical Co., Ltd.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lifitegrast Ophthalmic Solution Market: Growing Awareness Regarding Dry Eye Syndrome among People is Expected to Drive the Market Growth here

News-ID: 412247 • Views: 307

More Releases from TMR

01-24-2020 | Health & Medicine
TMR
Myasthenia Gravis Market : Insights and Emerging Trends by 2025
Healthcare scientists, researchers, and practitioners are under constantly pressure to reinvent current medical practices to improve treatment and diagnosis. This factor has always kept the medical fraternity on its toes, and has often led to improvements in generic treatment mechanisms for common diseases and disorder. Healthcare resource utilization studies suggest the US Healthcare industry is majorly affected by the heavy incidence of refractory myasthenia gravis. Not only does the high
01-24-2020 | Health & Medicine
TMR
Chronic Myelogenous Leukemia Treatment Market : Trends Research and Projections …
The demand within the global market for chronic myelogenous leukaemia treatment has been rising on account of advancements in the worldwide healthcare sector. The presence of a robust domain for cancer treatment is expected to improve the chances of market growth. The vendors operating in the global chronic myelogenous leukaemia treatment have made concerted efforts to improve their revenue index. The relation of the global chronic myelogenous leukaemia treatment market
01-24-2020 | Health & Medicine
TMR
Sexually Transmitted Diseases (STDs) Drug Market : Research and Analyzed Report …
Transparency Market Research (TMR) observes, the global sexually transmitted diseases (STDs) drug market is highly competitive due to presence of several strong players. The key players are investing on the research and development activities for developing a novel drugs in order to be a part of competition. Some of the key players in the global sexually transmitted diseases drug market includes Pfizer INC, Bayer Healthcare, Hoffmann La Roche, Eli Lilly,
01-24-2020 | Health & Medicine
TMR
Plasma Protease C1-inhibitor Treatment Market : Growth Analysis, Trends and Scop …
The vendor landscape of the global market for plasma protease c1-inhibitor treatment market is largely consolidated with a handful of companies collectively accounting for a lion's share in the market and maintaining a tough level of competition, observes Transparency Market Research in a recent report. The company Shire plc. held the dominant spot in the market, thanks to its expansive product portfolio and extensive geographical reach. Other leading companies in

All 5 Releases


More Releases for Xiidra

Lifitegrast Ophthalmic Solution Market Size, Status and Forecast to 2024
Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in
Lifitegrast Ophthalmic Solution Market Segments and Key Trends 2016 - 2024
Lifitegrast Ophthalmic Solution Market: Overview Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick
Lifitegrast Ophthalmic Solution Market to Reflect Impressive Growth Rate During …
Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in
Lifitegrast Ophthalmic Solution Market | Analysis and Forecast up to 2024
Lifitegrast Ophthalmic Solution Market: Overview Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick
02-22-2017 | Health & Medicine
TMR
Global Lifitegrast Ophthalmic Solution Market is Driven by Rising Prevalence of …
Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in
02-03-2017 | Health & Medicine
TMR
Lifitegrast Ophthalmic Solution Market: Increasing Demand for Advance Treatment …
Lifitegrast is an integrin antagonist that reduces T-cell-mediated inflammation associated with dry eye disease (DED). This molecule was in pipeline for past few years and several clinical trials have been performed to test its efficacy in treating the signs and symptoms of dry eye syndrome. Avail a Sample of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13844 In July 2016, lifitegrast ophthalmic solution (5%) under the brand name Xiidra by Shire plc was granted an approval from